Nuvation Bio Q3 net loss $27.2M; cash $673.9M; NUV-868 Phase 1b on track

Nuvation Bio Inc.

2022-Q3 EPS reported -$0.39

Net loss of $27.2M ($0.12/share) vs $22.0M ($0.11/share) in Q3 2021.
Cash, cash equivalents and marketable securities of $673.9M as of Sep 30, 2022; runway through 2028.
R&D expenses $21.3M (incl. $1.6M restructuring and $5.7M contract termination costs).
Phase 1 monotherapy of NUV-868 dosing; Phase 1b combo with olaparib/enzalutamide expected by end of 2022.
DDC platform first clinical candidate nomination on track for end of 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvation Bio Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $27.2 million, or $(0.12) per share, EPS $(0.12) per share.

Period: the third quarter ended September 30, 2022
Net income: net loss of $27.2 million, or $(0.12) per share
EPS: $(0.12) per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-276899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.